Skip to main content

Novo Nordisk A/S (NVO) Stock

Novo Nordisk A/S Stock Details, Movements and Public Alerts

Stock Details

Novo Nordisk A/S (NVO), a prominent company in the healthcare sector within the drug manufacturers - general industry, is based in USA and primarily trades on the NYSE.Currently, the stock is trading at $47.68. Over the past 52 weeks, it has ranged between $43.08 and $91.28. This places the current price at 52.2% of its 52-week high and 10.7% above its 52-week low. Recent trading volume was recorded at 35,816,366. The 14-day Relative Strength Index (RSI) stands at 33.24, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $56.45 by 15.54%. Similarly, it is below its 200-day moving average of $66.75 by 28.57%. The MACD histogram is -0.55, indicating bearish momentum (MACD Line: -1.24, Signal Line: -0.69). The International Securities Identification Number (ISIN) for this stock is US6701002056.

52-Week Range

$91.28 - $43.08

-47.77% from high · +10.68% from low

Avg Daily Volume

11,407,769

20-day average

100-day avg: 14,763,628

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

13.12

Below market average

Forward P/E

12.76

Earnings expected to grow

PEG Ratio

3.99

Potentially overvalued

Price to Book

6.90

EV/EBITDA

9.04

EPS (TTM)

$3.63

Price to Sales

0.79

Beta

0.40

Less volatile than market

Q:How is NVO valued relative to its earnings and growth?
Novo Nordisk A/S trades at a P/E ratio of 13.12, which is below the market average of approximately 20. This lower valuation could indicate the market has modest growth expectations, or it might represent an undervalued opportunity if the fundamentals are strong. Looking ahead, the forward P/E of 12.76 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 3.99 indicates a premium valuation even accounting for growth.
Q:What is NVO's risk profile compared to the market?
With a beta of 0.40, Novo Nordisk A/S is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 6.90 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

33.10%

Operating Margin

44.50%

EBITDA

$153.29B

Return on Equity

60.70%

Return on Assets

17.40%

Revenue Growth (YoY)

-7.60%

Earnings Growth (YoY)

-4.70%

Q:How profitable and efficient is NVO's business model?
Novo Nordisk A/S achieves a profit margin of 33.10%, meaning it retains $33.10 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 44.50% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 60.70% and ROA at 17.40%, the company generates strong returns on invested capital.
Q:What are NVO's recent growth trends?
Novo Nordisk A/S's revenue declined by 7.60% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 4.70% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against DRUG MANUFACTURERS - GENERAL industry averages for proper context.

Dividend Information

Dividend Per Share

$11.70

Dividend Yield

3.90%

Ex-Dividend Date

Mar 30, 2026

Dividend Date

Aug 26, 2025

Q:What dividend income can investors expect from NVO?
Novo Nordisk A/S offers a dividend yield of 3.90%, paying $11.70 per share annually. This above-average yield of 2-4% provides meaningful income while still allowing the company to reinvest for growth. It compares favorably to the S&P 500 average and offers competitive returns versus bonds in the current rate environment. To receive the next dividend, shares must be purchased before the ex-dividend date of Mar 30, 2026.
Q:How reliable is NVO's dividend for long-term investors?
The dividend sustainability can be assessed through the payout ratio - Novo Nordisk A/S pays $11.70 per share in dividends against earnings of $3.63 per share, resulting in a payout ratio of 100.00%. This very high payout exceeding 90% raises sustainability concerns, as nearly all earnings go to dividends. Any earnings decline could force a dividend cut. The next dividend payment is scheduled for Aug 26, 2025.

Company Size & Market

Market Cap

$244.5B

Revenue (TTM)

$309.06B

Revenue/Share (TTM)

$69.56

Shares Outstanding

3.37B

Book Value/Share

$6.89

Asset Type

Common Stock

Q:What is NVO's market capitalization and position?
Novo Nordisk A/S has a market capitalization of $244.5B, classifying it as a mega-cap stock (over $200B). These are the largest, most established companies globally, typically offering stability and liquidity but with more modest growth potential. Mega-caps often pay dividends and weather economic downturns better than smaller companies. With 3.37B shares outstanding, the company's ownership is widely distributed. As a major player in the DRUG MANUFACTURERS - GENERAL industry, it competes with other firms in this sector.
Q:How does NVO's price compare to its book value?
Novo Nordisk A/S's book value per share is $6.89, while the current stock price is $47.68, resulting in a price-to-book (P/B) ratio of 6.92. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$54.82

14.97% upside potential

Analyst Recommendations

Strong Buy

0

Buy

6

Hold

5

Sell

2

Strong Sell

0

Q:How reliable are analyst predictions for NVO?
13 analysts cover NVO with 46% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $54.82 implies 15.0% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on NVO?
Current analyst recommendations:06 Buy, 5 Hold, 2 Sell, 0The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Feb 8, 2026, 02:24 AM

Technical Indicators

RSI (14-day)

33.24

Neutral

50-Day Moving Average

$56.45

-15.54% below MA-50

200-Day Moving Average

$66.75

-28.57% below MA-200

MACD Line

-1.24

MACD Signal

-0.69

MACD Histogram

-0.55

Bearish

Q:What does NVO's RSI value tell investors?
The RSI (Relative Strength Index) for NVO is currently 33.24, indicating the stock is showing bearish momentum (30-40 range). Selling pressure is evident but not extreme. This often occurs during pullbacks in uptrends or early stages of downtrends. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret NVO's MACD and moving average crossovers?
MACD analysis shows the MACD line at -1.24 below the signal line at -0.69, with histogram at -0.55. This bearish crossover indicates downward pressure. The 50-day MA ($56.45) is below the 200-day MA ($66.75), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Oct 29, 2025, 12:42 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for NVO and get notified when the price changes.

Stay Ahead of the Market with Novo Nordisk A/S Alerts

Set up price alerts for Novo Nordisk A/S and get notified instantly when the price hits your target. Never miss an important price movement again.